Clinical trials: Urinary Urgency Incontinence
Urinary Bladder, Overactive
A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder
The purpose of the study is to evaluate the effect of YM178 in patients with overactive bladder for 12-week administration.
- Trial name
- NCT00966004
- Testing
- YM178, tolterodine
- Where
- 4 sites in Japan
- Volunteers
- 1,139 people
- Sponsor
- Astellas Pharma Inc
Overactive Bladder, Urge Incontinence
Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence
This trial is a prospective, multicenter, single-arm study of the safety and effectiveness of eCoinTM tibial nerve stimulation in subjects having overactive bladder (OAB) with urgency urinary incontinence (UUI).
- Conditions
- Overactive Bladder, Urge Incontinence, Incontinence, Urinary, Urinary Urge Incontinence
- Trial name
- NCT03556891
- Testing
- eCoin Tibial Nerve Stimulation
- Where
- 15 sites in United States
- Volunteers
- 133 people
- Sponsor
- Valencia Technologies Corporation
Overactive Bladder
A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder
This study is designed to assess the efficacy and safety of a flexible dose regimen of fesoterodine on urgency urinary incontinence (UUI) episodes in vulnerable elderly subjects with overactive bladder (OAB).
- Trial name
- NCT00928070
- Testing
- Fesoterodine
- Where
- 125 sites in United States
- Volunteers
- 566 people
- Sponsor
- Pfizer
Urinary Incontinence
Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction
The primary objective of the trial is to evaluate the effect of tolterodine ER plus tamsulosin versus placebo on patient perception of overall treatment benefit in men who have frequency and urgency, with or without urinary urge…
- Trial name
- NCT00147654
- Testing
- Tolterodine ER 4 mg QD, Tamsulosin 0.4 mg QD
- Where
- 95 sites in United States
- Volunteers
- 830 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Overactive Bladder, Urinary Urge Incontinence
InterStim Basic Evaluation Lead Post-Market Clinical Follow-up Study
Post-market clinical follow-up for continued assessment of safety and performance of the InterStim basic evaluation lead and foramen needle(s) used during a therapy evaluation.
- Conditions
- Overactive Bladder, Urinary Urge Incontinence, Urgency-frequency Syndrome
- Trial name
- BASIC (NCT04016324)
- Testing
- InterStim Basic Evaluation lead and foramen needle
- Where
- 15 sites in United States, Canada and 2 more
- Volunteers
- 110 people
- Sponsor
- MedtronicNeuro
Urinary Bladder Diseases, Urinary Bladder Overactive
A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)
The purpose of this study was to see if adding a new type of medication recently approved to treat overactive bladder (mirabegron) to an antimuscarinic treatment (solifenacin) would be more effective in controlling incontinence…
- Conditions
- Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases
- Trial name
- BESIDE (NCT01908829)
- Testing
- mirabegron 25 mg, mirabegron 50 mg, solifenacin 5 mg
- Where
- 219 sites in United States, Armenia and 29 more
- Volunteers
- 2,174 people
- Sponsor
- Astellas Pharma Europe Ltd.
Urgency Incontinence, Urinary Bladder Overactive
A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice
A study to understand the impact of Betmiga® on patients quality of life, satisfaction with treatment, how long patients remain on treatment, patterns of healthcare resource utilisation, and safety as prescribed by the physicians…
- Conditions
- Urgency Incontinence, Urinary Bladder Overactive, Overactive Bladder, Urologic Diseases
- Trial name
- BELIEVE (NCT02320773)
- Testing
- Betmiga®
- Where
- 60 sites in Czechia, Denmark and 6 more
- Volunteers
- 863 people
- Sponsor
- Astellas Pharma Europe Ltd.
Overactive Bladder, Urge Incontinence
eCoin for OAB Feasibility Follow-on Study
This trial is a prospective, multicenter, single-arm follow-on study will evaluate the safety and effectiveness of eCoinTM tibial nerve stimulation in subjects with urgency urinary incontinence (UUI) as defined by the American…
- Conditions
- Overactive Bladder, Urge Incontinence, Incontinence, Urinary, Urinary Urge Incontinence
- Trial name
- NCT03655054
- Testing
- eCoin Tibial Nerve Stimulation
- Where
- 7 sites in United States, New Zealand
- Volunteers
- 23 people
- Sponsor
- Valencia Technologies Corporation
Overactive Bladder
Safety and Efficacy Study of Intravesical Instillations of BotuGelTM, Slow Release RTGel Based Botox® Formulations, in Idiopathic OAB Patients With Urinary Incontinence ("INTIMO2")
The study will investigate the safety and efficacy of UroGen's TC-3 Gel for sustained release of Botulinum Toxin A (BTX) in urinary bladder in patients with idiopathic overactive bladder.
- Trial name
- INTIMO2 (NCT02674269)
- Testing
- 300 IU of BotuGelTM (60ml), 400 IU of BotuGelTM (60ml), TC-3 Gel
- Where
- 2 sites in Israel
- Sponsor
- UroGen Pharma Ltd.
Overactive Bladder
Overactive Bladder Posterior Tibial Implantable MIcro STimulator - 1
Interventional, Prospective, Open Label study
- Trial name
- OPTIMIST-1 (NCT03019094)
- Testing
- The RENOVA tibial nerve stimulation system
- Sponsor
- BlueWind Medical
Urinary Incontinence, Urge
CAN-Stim Compared to SNS in Treatment of Urinary Urgency Incontinence With Wireless Neuromodulation Technology
This is a prospective, randomized, controlled, multi-center, study in which 150 evaluable subjects will be randomized 1:1 to receive either a Protect CAN-Stim or SNS InterStim® system.
- Trial name
- PROTECT (NCT02577302)
- Testing
- CAN-Stim - Protect CAN-Stim System, SNS - InterStim® System
- Where
- 15 sites in United States
- Volunteers
- 200 people
- Sponsor
- Uro Medical Corporation
Incontinence, Urinary and Urinary Bladder, Overactive, Overactive Bladder
Effects Of GW679769 On Bladder Nerve Function And Symptoms Of Overactive Bladder In Spinal Cord Injury Patients
This is a two-part study in which Part A will assess the effects of GW679769 after 1 dose on the function of the nerves that supply the bladder. The technique for measuring the nerves function is called Neurometry.
- Trial name
- NCT00332319
- Testing
- GW679769
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Overactive Bladder
A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency
This study is designed to assess the efficacy of a flexible dose regimen of fesoterodine on micturition related nocturnal urgency episodes.
- Trial name
- NCT00911937
- Testing
- Fesoterodine
- Where
- 112 sites in United States
- Volunteers
- 963 people
- Sponsor
- Pfizer
Urinary Incontinence, Urge
Sacral Nerve Stimulation to Treat Urgency Urinary Incontinence With Wireless Neuromodulation
The purpose of this pivotal study is to illustrate the safety and effectiveness of the StimGuard Sacral Nerve Stimulation (SNS) System in the treatment refractory urge incontinence.
- Trial name
- NCT02434874
- Testing
- StimGuard Sacral Nerve Stimulator System
- Where
- United States
- Sponsor
- Uro Medical Corporation
Overactive Bladder
A Confirmatory Study of KUC-7483 in Patients With Overactive Bladder
To evaluate the efficacy and the safety of KUC-7483 in overactive bladder patients.
- Trial name
- NCT01004315
- Testing
- KUC-7483, Tolterodine
- Where
- Japan
- Volunteers
- 750 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Urinary Bladder, Overactive
Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
The study is intended to test the safety, tolerability, efficacy of two doses of long term once daily (qd) treatment of Mirabegron in patients with symptoms of overactive bladder and secondly to compare these with active…
- Trial name
- TAURUS (NCT00688688)
- Testing
- Mirabegron, Tolterodine
- Where
- 308 sites in United States, Australia and 28 more
- Volunteers
- 2,792 people
- Sponsor
- Astellas Pharma Inc
Overactive Bladder (OAB), Refractory Overactive Bladder
Cefar URO - Symptomatic Treatment of Overactive Bladder
A Post-Market Prospective Clinical Investigation to collect PMCF data on the safety and performance of the Cefar URO device when using the preset program P4 (parameter setting: frequency 20Hz, pulse width 200μs) for the…
- Conditions
- Overactive Bladder (OAB), Refractory Overactive Bladder, Urinary Urgency and Frequency
- Trial name
- NCT06659536
- Testing
- Transcutaneous Tibial Nerve Stimulation (TTNS) with the Cefar Uro Device
- Where
- France
- Volunteers
- 53 people
- Sponsor
- DJO UK Ltd
Urinary Bladder Overactive, Urinary Bladder Diseases\Urologic Diseases
This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder
The purpose of this study was to examine how well two medicines (solifenacin succinate and mirabegron) combined work compared to each medicine alone in the treatment of bladder problems.
- Conditions
- Urinary Bladder Overactive, Urinary Bladder Diseases\Urologic Diseases, Overactive Bladder, Urgency Incontinence
- Trial name
- SYNERGY (NCT01972841)
- Testing
- Solifenacin succinate, Mirabegron
- Where
- 435 sites in United States, Argentina and 40 more
- Volunteers
- 3,527 people
- Sponsor
- Astellas Pharma Europe B.V.
Overactive Bladder, Urge Incontinence
A Real World Study of eCoin for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE)
A prospective, multicenter, single-arm study to evaluate the safety and effectiveness of the eCoin® implanted tibial nerve stimulator in subjects with urgency urinary incontinence (UUI).
- Conditions
- Overactive Bladder, Urge Incontinence, Incontinence, Urinary, Urinary Urge Incontinence
- Trial name
- RECIPE (NCT05685433)
- Testing
- eCoin Tibial Nerve Stimulation
- Where
- 22 sites in United States
- Volunteers
- 200 people
- Sponsor
- Valencia Technologies Corporation
Urinary Retention, Urinary Urge Incontinence
Axonics SacRal NeuromodulaTIon System RegisTRY Study
To assess the post-market clinical outcomes with use of the Axonics Sacral Neuromodulation System(s).
- Conditions
- Urinary Retention, Urinary Urge Incontinence, Urgency-Frequency, Fecal Incontinence
- Trial name
- ARTISTRY (NCT05064384)
- Where
- 27 sites in United States, Canada
- Volunteers
- 272 people
- Sponsor
- Axonics, Inc.